JAK Janus Kinase

Cat.No.	Name	Information
M3030	S-Ruxolitinib	S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M1820	Tofacitinib	Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM.
M1660	AZ 960	AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro.
M1646	AG490	AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
M1733	TG101348	TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1787	INCB18424	Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo.
M5944	Ruxolitinib phosphate	Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M3616	Tofacitinib citrate	Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
M2346	Filgotinib	Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
M2044	AZD1480	AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively.
M42103	DPP	DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand.
M42102	STAT3-IN-18	STAT3-IN-18 is a platinum (IV) complex with an axial ligand derived from sandalwood.
M41718	JAK-IN-28	JAK-IN-28 is a JAK inhibitor.
M41717	JAK-IN-29	JAK-IN-29 is a potent JAK inhibitor.
M41716	JAK kinase-IN-1	JAK kinase-IN-1 is a JAK inhibitor.
M41715	JAK-STAT-IN-1	JAK-STAT-IN-1 is a selective JAK-STAT inhibitor.
M41714	JAK2-IN-9	JAK2-IN-9 is a selective JAK2 inhibitor (IC50: 5 nM).
M41713	Lepzacitinib	Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3.
M41712	JAK1-IN-12	JAK1-IN-12 is a selective inhibitor of JAK1, with IC50 of 0.0246 μM.
M41711	HAT-SIL-TG-1&AT	HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects.
M41710	JAK-IN-26	JAK-IN-26 is an orally active JAK inhibitor with good pharmacokinetic characteristics.
M41709	JAK/HDAC-IN-2	JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor.
M41708	JAK1-IN-11	JAK1-IN-11 is a potent inhibitor of JAK, with IC50s of 0.02 nM (JAK1), and 0.44 nM (JAK2), respectively.
M41707	JAK3-IN-14	JAK3-IN-14 is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively.
M41706	JAK1-IN-10	JAK1-IN-10, a cyano-substituted cyclic hydrazine derivative, is a potent and selective JAK1 inhibitor.
M41705	JAK-IN-25	JAK-IN-25 is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively.
M41704	JAK-IN-30	JAK-IN-30 is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively.
M41703	JAK/HDAC-IN-3	JAK/HDAC-IN-3 is a dual JAK and HDAC inhibitor, with IC50 values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively.
M41702	JAK-IN-27	JAK-IN-27 is an orally active and potent JAKS family kinase inhibitor with IC50s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively.
M41701	JAK-IN-31	JAK-IN-31 is a JAK inhibitor with IC50 ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for JAK1, JAK2, JAK3 and Tyk2 respectively.

By Signaling Pathways

By Product Type

Signaling Pathways

JAK Janus Kinase

Get to Know Us

Customer Support

Resources

Contact Us